Making Every Breath CountTM
Transforming the treatment of severe emphysema with a unique bronchoscopic approach designed to reduce trapped air associated with hyperinflation.
Making Every Breath CountTM
Transforming the treatment of severe emphysema with a unique bronchoscopic approach designed to reduce trapped air associated with hyperinflation.
The Unmet Need in Emphysema Care
Emphysema is a chronic lung disease marked by damage to the air sacs and small airways in the lungs, causing air to become trapped and making breathing difficult. Ongoing shortness of breath can severely impact daily life.
While treatment options exist, many current approaches are limited by narrow patient eligibility, procedural complexity, and challenges integrating into real-world care settings. As a result, many people with emphysema continue to have few viable options.
Emphysema is a chronic lung disease marked by damage to the air sacs and small airways in the lungs, causing air to become trapped and making breathing difficult. Ongoing shortness of breath can severely impact daily life.
While treatment options exist, many current approaches are limited by narrow patient eligibility, procedural complexity, and challenges integrating into real-world care settings. As a result, many people with emphysema continue to have few viable options.
Apreo BREATHE
Airway Scaffold
The Apreo BREATHE Airway Scaffold is an investigational, bronchoscopic treatment using a self-expanding nitinol scaffold designed to tent open targeted airways to help release trapped air and support easier breathing for people with severe emphysema.
The Apreo BREATHE Airway Scaffold is an Investigational Device. Limited by United States law to investigational use.
The Apreo BREATHE Airway Scaffold is an investigational, bronchoscopic treatment using a self-expanding nitinol scaffold designed to tent open targeted airways to help release trapped air and support easier breathing for people with severe emphysema.
The Apreo BREATHE Airway Scaffold is an Investigational Device. Limited by United States law to investigational use.
Airway Support
Designed to improve lung function by reducing hyperinflation and restoring breathing capacity
Quality of Life
Aims to reduce breathlessness and support greater participation in daily activities
Minimalist Structure
Flexible, low-profile design intended to minimize foreign body reaction, preserve side branches and enable treatment in both lungs
Broad Access
Potential to expand patient access with broad eligibility and seamless workflow integration
About Apreo Health
Apreo Health is dedicated to pioneering safe, transformative solutions for lung disease. We serve patients with passion, integrity and a commitment to restoring their health and quality of life.
Core values
Co-founder
Co-founder
News
Follow the latest developments at Apreo Health, from product innovation and clinical learnings to important company milestones.
Apreo Health® Adds Independent Director and Strategic Investor
MENLO PARK, Calif., May 13, 2026 /PRNewswire/ — Apreo Health, a clinical-stage medical device company pioneering a tissue-sparing treatment for severe emphysema, today announced the appointment of David Amerson to its Board of Directors and a strategic investment from OSF Ventures, the corporate investment arm of OSF HealthCare. The company also announced it will present new clinical data at the American […]
Apreo Health® Announces Presentation & Publication of FIH Clinical Data
MENLO PARK, Calif.–(BUSINESS WIRE)–Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced the presentation of first-in-human six-month clinical data from the BREATHE 1&2 trials in a late-breaking abstract session at the American Thoracic Society (ATS) 2025 International Conference in San Francisco. The study was simultaneously published in […]
Apreo Health to Present First-in-Human Data for Novel Airway Scaffold at ATS 2025
MENLO PARK, Calif.–(BUSINESS WIRE)–Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced its emergence from stealth and upcoming presentation of first-in-human clinical data at the American Thoracic Society (ATS) 2025 International Conference, May 16-21 in San Francisco. The company’s BREATHE 1&2 feasibility studies will be presented as […]